Eukaryotic translation initiation factor 4 gamma 1 (1248-1256)

Eukaryotic translation initiation factor 4 gamma 1 (UniProt:Q04637)

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-058

Synonyms/Alias:Eukaryotic translation initiation factor 4 gamma 1 (1248-1256)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
AIIEEYLHL
Areas of Interest
Antigen-presenting Cells; Cancer Research

Eukaryotic translation initiation factor 4 gamma 1 (1248-1256) is a synthetic peptide fragment derived from the C-terminal region of the eIF4G1 protein, a pivotal scaffolding component of the eukaryotic translation initiation complex. As a key mediator in the assembly of the eIF4F complex, eIF4G1 orchestrates the recruitment of ribosomes to mRNA, thereby regulating cap-dependent translation initiation in eukaryotic cells. The 1248-1256 peptide segment represents a functionally significant motif implicated in protein-protein interactions critical for translation regulation. Researchers utilize this peptide to dissect the molecular mechanisms underlying translation initiation, study protein binding interfaces, and explore post-translational modifications that influence translational control.

Protein-protein interaction studies: The eIF4G1 (1248-1256) peptide is frequently employed in in vitro binding assays to map the interaction sites between eIF4G1 and its binding partners, such as eIF4E, eIF4A, or regulatory proteins. By using the peptide as a competitive inhibitor or as a probe in pull-down or surface plasmon resonance experiments, scientists can elucidate the specific contributions of this C-terminal motif to complex assembly and stability. Such studies facilitate a deeper understanding of translation initiation regulation and the modulation of protein synthesis under varying cellular conditions.

Peptide-based inhibitor development: The defined sequence of this synthetic fragment makes it a valuable template for the rational design of small-molecule or peptide-based inhibitors targeting the eIF4G1 interface. By mimicking or disrupting natural interaction motifs, researchers can use the peptide to screen for compounds that modulate eIF4F complex formation. This approach is particularly relevant for identifying molecular tools to probe translation control pathways or to develop research agents that selectively alter protein synthesis in model systems.

Epitope mapping and antibody validation: The eIF4G1 (1248-1256) peptide serves as a precise antigenic determinant in immunological studies, supporting the generation and validation of sequence-specific antibodies. By employing the peptide in enzyme-linked immunosorbent assays (ELISA), western blot, or immunoprecipitation protocols, laboratories can characterize antibody specificity and affinity for the targeted region of eIF4G1. This application is crucial for ensuring the reliability of immunodetection reagents used in translational research and proteomics.

Phosphorylation and post-translational modification analysis: The C-terminal domain of eIF4G1, encompassing residues 1248-1256, is a candidate site for regulatory post-translational modifications such as phosphorylation. Synthetic peptides corresponding to this region are utilized as substrates in kinase assays or as standards in mass spectrometry-based studies to identify and quantify modifications. These investigations provide insight into the dynamic regulation of translation initiation by signaling pathways and enable the functional characterization of modification-dependent protein interactions.

Structural and biophysical characterization: The well-defined sequence and physicochemical properties of the eIF4G1 (1248-1256) peptide make it suitable for structural studies using nuclear magnetic resonance (NMR), circular dichroism, or crystallography. Researchers use the peptide to analyze secondary structure propensity, conformational dynamics, and its interaction with other biomolecules. Such analyses contribute to a mechanistic understanding of how specific motifs within eIF4G1 facilitate the formation and regulation of the eukaryotic translation initiation complex at the molecular level.

Source#
Homo sapiens (human)
Epitope
1248-1256
Restricting HLA
HLA-A2
References
Ramila Philip; J Proteome Res 2007

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
cGMP Peptide ServicePeptide Nucleic Acids SynthesisPeptide Modification ServicesPeptide Synthesis ServicesCustom Conjugation ServicePeptide Analysis ServicesPeptide CDMOEpitope Mapping Services
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers